Evidence has revealed the high expression of CD52 in CD34+ stem cells of AML (5q-) patients and a significantly negative correlation between the CD52 expression value and the prognosis of AML (59), which is consistent with our results. This evidence concerns the gene CD34 and acute myeloid leukemia.